Could Plasma Cystatin C Be Useful As A Marker Of Hemodialysis Low Molecular Weight Proteins Removal?

A Campo,G Lanfranco,L Gramaglia,F Goia,R Cottino,V Giusto
DOI: https://doi.org/10.1159/000080677
2004-01-01
Abstract:Background: Plasma cystatin (pCyst) is a well-assessed tool for measuring renal function, and it could also play a part in hemodialysis adequacy. Methods: pCyst and other uremic toxins ( urea, creatinine, parathyroid hormone, prolactin) were assessed before and after a dialysis session in 18 hemodialysis patients: 7 on bicarbonate hemodialysis (BHD) and 11 on mixed convective dialysis (MCD; 6 standard hemodiafiltration and 5 acetate-free biofiltration). Plasma levels and reduction ratios (RR) were then compared between the BHD and MCD groups. Results: The mean pre-dialysis pCyst level is nearly the same in both groups (5.3 +/- 0.8 vs. 5.7 +/- 1 mg/l, p = ns), although a substantial decrease occurs after MCD only (mean 2.4 +/- 1 vs. 6.2 +/- 2.2 mg/l after BHD, p = 0.002). The mean pCyst RR (PCRR) of 55.5% after MCD is poorly related to prolactin and urea RR, fairly comparable to parathyroid hormone RR and very close to creatinine RR (58.4%). Conclusions: Only MCD removes pCyst, but the amount of removal is different for other low molecular weight proteins ( prolactin and parathyroid hormone) and similar for creatinine, a classic 'little molecule'. In view of the discrepancy of these findings, the use of pCyst in hemodialysis still seems premature and needs further studies. Copyright (C) 2004 S. Karger AG, Basel.
What problem does this paper attempt to address?